CN102762590B - 人源化的FcγR小鼠 - Google Patents

人源化的FcγR小鼠 Download PDF

Info

Publication number
CN102762590B
CN102762590B CN201080064262.4A CN201080064262A CN102762590B CN 102762590 B CN102762590 B CN 102762590B CN 201080064262 A CN201080064262 A CN 201080064262A CN 102762590 B CN102762590 B CN 102762590B
Authority
CN
China
Prior art keywords
human
chain
mouse
gene
endogenous
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201080064262.4A
Other languages
English (en)
Chinese (zh)
Other versions
CN102762590A (zh
Inventor
L·麦克唐纳
涂纳新
C·古尔
S·史蒂文斯
A·J·墨菲
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Regeneron Pharmaceuticals Inc
Original Assignee
Regeneron Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43601078&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN102762590(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Regeneron Pharmaceuticals Inc filed Critical Regeneron Pharmaceuticals Inc
Priority to CN201410471291.2A priority Critical patent/CN104232589B/zh
Publication of CN102762590A publication Critical patent/CN102762590A/zh
Application granted granted Critical
Publication of CN102762590B publication Critical patent/CN102762590B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0276—Knock-out vertebrates
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70535—Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5014—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/15—Humanized animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/15—Animals comprising multiple alterations of the genome, by transgenesis or homologous recombination, e.g. obtained by cross-breeding
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/035—Animal model for multifactorial diseases
    • A01K2267/0387—Animal model for diseases of the immune system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Environmental Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Animal Husbandry (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pathology (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Analytical Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Rheumatology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Diabetes (AREA)
  • General Physics & Mathematics (AREA)
  • Endocrinology (AREA)
CN201080064262.4A 2009-12-21 2010-12-17 人源化的FcγR小鼠 Active CN102762590B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201410471291.2A CN104232589B (zh) 2009-12-21 2010-12-17 人源化的FcγR小鼠

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US28856209P 2009-12-21 2009-12-21
US61/288,562 2009-12-21
PCT/US2010/060925 WO2011084664A1 (en) 2009-12-21 2010-12-17 HUMANIZED FCγ R MICE

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201410471291.2A Division CN104232589B (zh) 2009-12-21 2010-12-17 人源化的FcγR小鼠

Publications (2)

Publication Number Publication Date
CN102762590A CN102762590A (zh) 2012-10-31
CN102762590B true CN102762590B (zh) 2015-11-25

Family

ID=43601078

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201080064262.4A Active CN102762590B (zh) 2009-12-21 2010-12-17 人源化的FcγR小鼠
CN201410471291.2A Active CN104232589B (zh) 2009-12-21 2010-12-17 人源化的FcγR小鼠

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201410471291.2A Active CN104232589B (zh) 2009-12-21 2010-12-17 人源化的FcγR小鼠

Country Status (26)

Country Link
US (9) US8658154B2 (enExample)
EP (3) EP3498730B1 (enExample)
JP (4) JP5595517B2 (enExample)
KR (4) KR101862277B1 (enExample)
CN (2) CN102762590B (enExample)
AU (3) AU2010339863B2 (enExample)
CA (2) CA3000246C (enExample)
CY (1) CY1120316T1 (enExample)
DK (1) DK2516457T3 (enExample)
ES (1) ES2671188T3 (enExample)
HK (1) HK1257001A1 (enExample)
HR (1) HRP20180911T1 (enExample)
HU (1) HUE038684T2 (enExample)
IL (4) IL220365A (enExample)
LT (1) LT2516457T (enExample)
MY (1) MY156743A (enExample)
NO (1) NO2516457T3 (enExample)
PL (1) PL2516457T3 (enExample)
PT (1) PT2516457T (enExample)
RS (1) RS57280B1 (enExample)
RU (1) RU2549695C2 (enExample)
SG (3) SG10201408415PA (enExample)
SI (1) SI2516457T1 (enExample)
SM (1) SMT201800296T1 (enExample)
TR (1) TR201808011T4 (enExample)
WO (1) WO2011084664A1 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO2516457T3 (enExample) 2009-12-21 2018-08-11
RU2634417C2 (ru) 2011-10-28 2017-10-26 Регенерон Фармасьютикалс, Инк. Гуманизированные il-6 и рецептор il-6
US20160058891A1 (en) * 2011-11-01 2016-03-03 Roche Glycart Ag In vivo adcc model
EP3939423B1 (en) * 2012-11-05 2024-03-06 Regeneron Pharmaceuticals, Inc. Genetically modified non-human animals and methods of use thereof
EP3842528A1 (en) 2013-09-18 2021-06-30 Kymab Limited Methods, cells and organisms
RU2674910C2 (ru) * 2013-10-15 2018-12-13 Регенерон Фармасьютикалс, Инк. Животные с гуманизированным геном il-15
MX388127B (es) 2013-12-11 2025-03-19 Regeneron Pharma Metodos y composiciones para la modificacion dirigida de un genoma.
KR102846903B1 (ko) * 2014-03-21 2025-08-20 리제너론 파마슈티칼스 인코포레이티드 단일 도메인 결합 단백질을 생산하는 비-인간 동물
HUE051088T2 (hu) 2014-04-08 2021-03-01 Regeneron Pharma Humanizált FC-gamma receptorokkal rendelkezõ nem humán élõlények
CN111118047B (zh) 2014-05-30 2023-09-22 再生元制药公司 人源化二肽基肽酶iv(dpp4)动物
LT3230320T (lt) * 2014-12-09 2021-01-11 Regeneron Pharmaceuticals, Inc. Gyvūnai, išskyrus žmogų, turintys humanizuotą diferenciacijos klasterio 274 geną
FI3282835T3 (fi) * 2015-04-13 2023-07-20 Regeneron Pharma Humanisoituja sirpa-il15-poistogeenisiä hiiriä ja niiden käyttömenetelmiä
CN107529739B (zh) * 2015-04-30 2021-01-08 株式会社特殊免疫研究所 表达人特定分子和人Fcγ受体家族的转基因非人动物
CN113831407B (zh) 2016-05-20 2024-06-11 瑞泽恩制药公司 用于使用多个引导rna来破坏免疫耐受性的方法
US11879014B2 (en) * 2017-03-17 2024-01-23 Tusk Therapeutics Ltd. Method of treating cancer or depleting regulatory T cells in a subject by administering a human IGG1 anti-CD25 antibody
KR20250121150A (ko) 2018-03-26 2025-08-11 리제너론 파마슈티칼스 인코포레이티드 치료제를 시험하기 위한 인간화된 설치류
JP6935383B2 (ja) 2018-09-27 2021-09-15 公益財団法人実験動物中央研究所 免疫不全マウス
EP3861854B1 (en) * 2018-09-27 2025-01-22 Central Institute for Experimental Medicine and Life Science Immunodeficient mouse
SG11202107589PA (en) 2019-02-22 2021-08-30 Regeneron Pharma Rodents having genetically modified sodium channels and methods of use thereof
CN113614238B (zh) * 2019-03-28 2024-10-22 公益财团法人实中研 免疫缺陷小鼠
KR20230147048A (ko) 2020-12-16 2023-10-20 리제너론 파마슈티칼스 인코포레이티드 인간화 Fc 알파 수용체를 발현하는 마우스
CN114410643B (zh) * 2021-02-02 2024-08-02 百奥赛图(北京)医药科技股份有限公司 FcRn基因人源化的非人动物及其构建方法和应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995028959A1 (en) * 1994-04-22 1995-11-02 Sloan-Kettering Institute For Cancer Research MICE MUTANT FOR Fc RECEPTORS AND METHOD OF TREATING AUTOIMMUNE DISEASE
US6676927B1 (en) * 1999-01-20 2004-01-13 The Rockefeller University Animal model and methods for its use in the selection of cytotoxic antibodies

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE68929256T2 (de) 1988-05-27 2001-05-17 Applied Research Systems Ars Holding N.V., Curacao Humaner Rezeptor Fc(gamma)RIII
JP2938569B2 (ja) * 1990-08-29 1999-08-23 ジェンファーム インターナショナル，インコーポレイティド 異種免疫グロブリンを作る方法及びトランスジェニックマウス
US5258359A (en) * 1991-08-02 1993-11-02 Monsanto Company Glyphosant-containing herbicidal compositions comprising acetylenic diol rainfastness enhancing agents
WO1994006908A1 (en) 1992-09-11 1994-03-31 The Regents Of The University Of California Transgenic non-human animals having targeted lymphocyte transduction genes
US6111166A (en) * 1994-09-19 2000-08-29 Medarex, Incorporated Transgenic mice expressing human Fcα and β receptors
CA2273194C (en) 1996-12-03 2011-02-01 Abgenix, Inc. Transgenic mammals having human ig loci including plural vh and vk regions and antibodies produced therefrom
US5899312A (en) * 1997-07-22 1999-05-04 Lucent Technologies Inc Anti-fraud string grabbing device
FR2807767B1 (fr) 2000-04-12 2005-01-14 Lab Francais Du Fractionnement Anticorps monoclonaux anti-d
JP2003531149A (ja) 2000-04-13 2003-10-21 ザ・ロツクフエラー・ユニバーシテイ 抗体由来の免疫応答の増強
CN101498731A (zh) * 2000-05-18 2009-08-05 日本烟草产业株式会社 抗协同刺激信号转导分子ailim的人单克隆抗体及其药物用途
US7413031B2 (en) 2000-07-18 2008-08-19 The Charles Machine Works, Inc. Apparatus and method for maintaining control of a drilling machine
US6586251B2 (en) 2000-10-31 2003-07-01 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
FR2822161B1 (fr) 2001-03-15 2003-09-19 Genoway Cellule et animal transgenique modelisant les reponses humaines allergiques mediees par les ige, et leurs utilisations
JP4653915B2 (ja) 2001-10-29 2011-03-16 独立行政法人科学技術振興機構 全身性エリテマトーデスモデル非ヒト動物
US20040132101A1 (en) * 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
WO2003104459A1 (en) 2002-06-07 2003-12-18 Arthron Limited Fcyriia transgenic animal model for autoimmune disease
JP2004147535A (ja) 2002-10-29 2004-05-27 Japan Science & Technology Agency ギラン・バレー症候群及び／又はフィッシャー症候群発症モデル非ヒト動物
WO2004060053A2 (en) * 2002-12-16 2004-07-22 Genentech, Inc. Transgenic mice expressing human cd20
FR2858235B1 (fr) 2003-07-31 2006-02-17 Lab Francais Du Fractionnement Utilisation d'anticorps optimises en adcc pour traiter les patients faibles repondeurs
BRPI0506771A (pt) * 2004-01-12 2007-05-22 Applied Molecular Evolution anticorpo, e, composição farmacêutica
DK1802193T3 (da) 2004-10-19 2014-06-10 Regeneron Pharma Fremgangsmåde til frembringelse af en homozygot mus til genetisk modifikation
WO2007041635A2 (en) * 2005-10-03 2007-04-12 Xencor, Inc. Fc variants with optimized fc receptor binding properties
SG170110A1 (en) 2006-03-10 2011-04-29 Macrogenics Inc Identification and engineering of antibodies with variant heavy chains and methods of using same
US20080003225A1 (en) 2006-06-29 2008-01-03 Henri Vie Method for enhancing the antibody-dependent cellular cytotoxicity (ADCC) and uses of T cells expressing CD16 receptors
EP2066349B1 (en) * 2006-09-08 2012-03-28 MedImmune, LLC Humanized anti-cd19 antibodies and their use in treatment of tumors, transplantation and autoimmune diseases
HU0700534D0 (en) * 2006-11-24 2007-10-29 Mezoegazdasagi Biotechnologiai Transgenic animal with enhanced immune response and method for the preparation thereof
KR101561020B1 (ko) 2007-07-31 2015-10-26 리제너론 파아마슈티컬스, 인크. 사람 ｃｄ20에 대한 사람 항체 및 이의 사용 방법
EP2245155A4 (en) * 2007-12-10 2011-05-25 Aliva Biopharmaceuticals Inc METHODS FOR SEQUENTIALLY REPLACING A TARGETED AREA BY HOMOLOGOUS RECOMBINATION
US20090271884A1 (en) 2008-03-07 2009-10-29 Regeneron Pharmaceuticals, Inc. ES Cell-Derived Mice From Diploid Host Embryo Injection
EP2318439A2 (en) * 2008-07-23 2011-05-11 Rappaport Family Institute for Research in the Medical Sciences Methods of altering peripheral b cell populations and uses thereof
NO2516457T3 (enExample) * 2009-12-21 2018-08-11
US8883496B2 (en) * 2009-12-21 2014-11-11 Regeneron Phamaceuticals, Inc. Humanized FcgR mice

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995028959A1 (en) * 1994-04-22 1995-11-02 Sloan-Kettering Institute For Cancer Research MICE MUTANT FOR Fc RECEPTORS AND METHOD OF TREATING AUTOIMMUNE DISEASE
US6676927B1 (en) * 1999-01-20 2004-01-13 The Rockefeller University Animal model and methods for its use in the selection of cytotoxic antibodies

Also Published As

Publication number Publication date
HRP20180911T1 (hr) 2018-07-13
US20140154701A1 (en) 2014-06-05
IL220365A0 (en) 2012-08-30
HK1257001A1 (en) 2019-10-11
JP2016093201A (ja) 2016-05-26
IL261257A (en) 2018-10-31
AU2010339863B2 (en) 2014-07-17
KR20200033981A (ko) 2020-03-30
AU2010339863A1 (en) 2012-07-12
JP5891259B2 (ja) 2016-03-22
KR101862277B1 (ko) 2018-06-01
US8658853B2 (en) 2014-02-25
JP5595517B2 (ja) 2014-09-24
NO2516457T3 (enExample) 2018-08-11
CN104232589B (zh) 2018-04-27
DK2516457T3 (en) 2018-06-18
AU2014210646A1 (en) 2014-08-28
US12036288B2 (en) 2024-07-16
CN102762590A (zh) 2012-10-31
KR101973524B1 (ko) 2019-09-02
IL261257B (en) 2019-12-31
US9687566B2 (en) 2017-06-27
US20210346522A1 (en) 2021-11-11
CA2784953A1 (en) 2011-07-14
CA3000246A1 (en) 2011-07-14
SG10202011814TA (en) 2021-01-28
JP2014132909A (ja) 2014-07-24
EP2516457B9 (en) 2021-09-29
JP2013514778A (ja) 2013-05-02
IL271083A (en) 2020-01-30
US10426848B2 (en) 2019-10-01
AU2014210645B2 (en) 2016-05-19
EP3336102A2 (en) 2018-06-20
EP3498730A1 (en) 2019-06-19
US9056130B2 (en) 2015-06-16
KR20180058860A (ko) 2018-06-01
US11020495B2 (en) 2021-06-01
WO2011084664A1 (en) 2011-07-14
AU2014210646B2 (en) 2016-06-23
US20140157445A1 (en) 2014-06-05
US20110154512A1 (en) 2011-06-23
TR201808011T4 (tr) 2018-06-21
CY1120316T1 (el) 2019-07-10
RU2549695C2 (ru) 2015-04-27
SG181690A1 (en) 2012-07-30
PT2516457T (pt) 2018-06-12
SI2516457T1 (en) 2018-08-31
IL242719A (en) 2017-09-28
CA3000246C (en) 2021-05-25
MY156743A (en) 2016-03-31
HUE038684T2 (hu) 2018-11-28
EP2516457B1 (en) 2018-03-14
EP3336102A3 (en) 2018-08-01
JP6073840B2 (ja) 2017-02-01
US9089599B2 (en) 2015-07-28
SG10201408415PA (en) 2015-01-29
KR102178064B1 (ko) 2020-11-12
KR102092744B1 (ko) 2020-03-24
US20150313195A1 (en) 2015-11-05
US20180015185A1 (en) 2018-01-18
EP3498730B1 (en) 2026-01-28
RS57280B1 (sr) 2018-08-31
AU2014210645A1 (en) 2014-08-28
IL220365A (en) 2016-11-30
KR20120102138A (ko) 2012-09-17
US20120260357A1 (en) 2012-10-11
US8658154B2 (en) 2014-02-25
CA2784953C (en) 2018-05-22
PL2516457T3 (pl) 2018-08-31
JP2014209923A (ja) 2014-11-13
CN104232589A (zh) 2014-12-24
KR20190045404A (ko) 2019-05-02
US20240424145A1 (en) 2024-12-26
LT2516457T (lt) 2018-06-11
EP2516457A1 (en) 2012-10-31
SMT201800296T1 (it) 2018-07-17
RU2012131296A (ru) 2014-01-27
ES2671188T3 (es) 2018-06-05
US20200061213A1 (en) 2020-02-27

Similar Documents

Publication Publication Date Title
CN102762590B (zh) 人源化的FcγR小鼠
US9221894B2 (en) Isolated cells from humanized FcγR mice
HK40009391A (en) Humanized fc gamma r mice
HK1171033A (en) Humanized fc gamma r mice
HK1171033B (en) Humanized fc gamma r mice

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant